US Edition
Cognition’s positive data from Phase 2 study of zervimesine in DLB presented at AAIC - BioTuesdays
Summary by biotuesdays.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Cognition’s positive data from Phase 2 study of zervimesine in DLB presented at AAIC - BioTuesdays
Cognition Therapeutics (NASDAQ: CGTX) has announced that James Edward Galvin, MD, MPH, will present results from the Phase 2 SHIMMER study of zervimesine (CT1812) in dementia with Lewy bodies (DLB) during an oral presentation at the Alzheimer’s Association International Conference (AAIC) on July 29, 2025, at 8:00 am ET. Dr. Galvin is director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine and wa…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
